Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

benzhydrocodone

- PMLiVE

Pfizer shares positive late-stage results for sasanlimab combination in bladder cancer

Approximately 10,500 people are diagnosed with bladder cancer in the UK every year

- PMLiVE

FDA accepts updated protocol for Annovis’ phase 3 Alzheimer’s disease study

The company hopes the revised protocol will accelerate the development timeline of buntanetap

- PMLiVE

Bristol Myers Squibb’s injectable Opdivo formulation granted FDA approval

Opdivo Qvantig can be administered in three to five minutes compared to 30 minutes for the drug’s IV form

- PMLiVE

BeiGene’s Tevimbra combination granted FDA approval to treat gastric cancer

Approximately 27,000 cases of the disease were diagnosed in the US in 2024

- PMLiVE

Pfizer’s Braftovi regimen receives FDA accelerated approval to treat colorectal cancer

The disease is the third most common type of cancer globally

- PMLiVE

FDA approves Organon’s Vtama cream to treat atopic dermatitis in adults and children

More than 26 million people in the US are affected by the inflammatory skin disease

- PMLiVE

Sanofi’s BTK inhibitor tolebrutinib granted FDA breakthrough designation for MS

The neurological disorder affects approximately 2.9 million people globally

- PMLiVE

AstraZeneca’s Imfinzi granted FDA approval in limited-stage small cell lung cancer

Small cell lung cancer accounts for approximately 15% of all lung cancer diagnoses

- PMLiVE

Sanofi receives FDA fast track designation for COVID-19/flu combination vaccines

The combined vaccine approach could simplify immunisation practices and lead to higher uptake

- PMLiVE

FDA approves Shorla Oncology’s Imkeldi to treat leukaemia and other cancers

The solution is an advanced liquid formulation of the tyrosine kinase inhibitor imatinib mesylate

- PMLiVE

FDA approves BridgeBio Pharma’s Attruby to treat rare heart disease ATTR-CM

Transthyretin amyloid cardiomyopathy affects up to 500,000 people worldwide

- PMLiVE

Pfizer’s Hympavzi receives EC approval to treat haemophilia A and B patients

The genetic blood disorder affects more than 800,000 people globally

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links